因赛集团：9月9日召开董事会会议

Group 1 - The core point of the article is that InnoCare Pharma announced the convening of its fourth board meeting to discuss the 2024 restricted stock incentive plan and its first vesting conditions [1] - InnoCare Pharma's revenue composition for the year 2024 is heavily reliant on the advertising industry, which accounts for 99.91% of total revenue, while other businesses contribute only 0.09% [1] - As of the latest report, InnoCare Pharma has a market capitalization of 6.6 billion yuan [2]